Propanc Biopharma (PPCB) Invested Capital (2011 - 2025)
Propanc Biopharma (PPCB) posted quarterly Invested Capital of $55000.0 for Q4 2025, down 86.58% year-over-year from $409799.0 in Q4 2024, and down 48.58% quarter-over-quarter from $106968.0 in Q3 2025.
Propanc Biopharma (PPCB) Invested Capital (2011 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Invested Capital for 15 consecutive years, with $55000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Invested Capital fell 86.58% year-over-year to $55000.0; the TTM figure through Dec 2025 stood at $1.1 million (down 35.82% YoY), while the FY2025 annual figure was $537921.0, up 34.71% from the prior year.
- Invested Capital slipped to $55000.0 in Q4 2025 per PPCB's latest filing, from $106968.0 in the prior quarter.
- Across five years, Invested Capital topped out at $1.1 million in Q1 2022 and bottomed at $32076.0 in Q3 2021.
- Historically, Invested Capital has averaged $471128.8 across 5 years, with a median of $404562.0 in 2024.
- Annual changes were most pronounced in 2021 — Invested Capital tumbled 96.88% — and 2022, when it soared 2748.36%.
- Propanc Biopharma's Invested Capital stood at $972670.0 in 2021, then slumped by 93.29% to $65280.0 in 2022, then surged by 953.39% to $687650.0 in 2023, then tumbled by 40.41% to $409799.0 in 2024, then plunged by 86.58% to $55000.0 in 2025.
- Business Quant data shows PPCB's Invested Capital at $55000.0 in Q4 2025, $106968.0 in Q3 2025, and $537921.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 190.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.45 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 380.00 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 55,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 55,000.00 |
| Sep 30, 2025 | 106,968.00 |
| Jun 30, 2025 | 537,921.00 |
| Mar 31, 2025 | 438,578.00 |
| Dec 31, 2024 | 409,799.00 |
| Sep 30, 2024 | 381,789.00 |
| Jun 30, 2024 | 399,325.00 |
| Mar 31, 2024 | 582,951.00 |
| Dec 31, 2023 | 687,650.00 |
| Sep 30, 2023 | 397,443.00 |
| Jun 30, 2023 | 390,539.00 |
| Mar 31, 2023 | 65,280.00 |
| Dec 31, 2022 | 65,280.00 |
| Sep 30, 2022 | 913,641.00 |
| Jun 30, 2022 | 926,438.00 |
| Mar 31, 2022 | 1.08 Mn |
| Dec 31, 2021 | 972,670.00 |
| Sep 30, 2021 | 32,076.00 |
| Jun 30, 2021 | 33,347.00 |
| Mar 31, 2021 | 950,180.00 |